{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.464.1003.1150","meta":{"versionId":"7","lastUpdated":"2021-11-02T01:01:56.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"NCQA PHEMUR Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2021-11-02"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1150","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.464.1003.1150"}],"version":"20211102","name":"SubstanceUseDisorderShortActingMedication","title":"Substance Use Disorder Short Acting Medication","status":"active","experimental":false,"date":"2021-11-02T01:01:56-04:00","publisher":"NCQA PHEMUR","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: The purpose of this Grouping value set is to represent concepts for short acting substance use disorder medications.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent generic, human use and prescribable naltrexone, buprenorphine and buprenorphine (oral, sublingual) medications.),(Exclusion Criteria: Excludes concepts that represent non-prescribable or branded drugs and excludes concepts that represent components or ingredients. Excludes long acting implant and injection medications.)","compose":{"include":[{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1153"]},{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1145"]},{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1146"]},{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1148"]},{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.1154"]}]},"expansion":{"identifier":"urn:uuid:b0979716-ec0a-4125-ad49-cc40e12199ba","timestamp":"2023-12-11T02:21:28-05:00","total":21,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1010600","display":"buprenorphine 2 MG / naloxone 0.5 MG Sublingual Film"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1010604","display":"buprenorphine 8 MG / naloxone 2 MG Sublingual Film"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1307056","display":"buprenorphine 4 MG / naloxone 1 MG Sublingual Film"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1307061","display":"buprenorphine 12 MG / naloxone 3 MG Sublingual Film"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1431076","display":"buprenorphine 1.4 MG / naloxone 0.36 MG Sublingual Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1431102","display":"buprenorphine 5.7 MG / naloxone 1.4 MG Sublingual Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1483744","display":"naltrexone hydrochloride 50 MG Oral Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1542390","display":"buprenorphine 2.1 MG / naloxone 0.3 MG Buccal Film"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1544851","display":"buprenorphine 4.2 MG / naloxone 0.7 MG Buccal Film"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1544854","display":"buprenorphine 6.3 MG / naloxone 1 MG Buccal Film"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1597568","display":"buprenorphine 11.4 MG / naloxone 2.9 MG Sublingual Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1597573","display":"buprenorphine 8.6 MG / naloxone 2.1 MG Sublingual Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1666338","display":"buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1864412","display":"buprenorphine 0.7 MG / naloxone 0.18 MG Sublingual Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"197623","display":"disulfiram 250 MG Oral Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"197624","display":"disulfiram 500 MG Oral Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"351264","display":"buprenorphine 2 MG Sublingual Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"351265","display":"buprenorphine 8 MG Sublingual Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"351266","display":"buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"351267","display":"buprenorphine 8 MG / naloxone 2 MG Sublingual Tablet"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"835726","display":"acamprosate calcium 333 MG Delayed Release Oral Tablet"}]}}